DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of recombinant (synthetic) proteins. The Company uses its technologies for the development and commercialization of recombinant proteins to treat kidney and neurological diseases. The Company’s focus is on chronic kidney disease (CKD) and acute ischemic stroke (AIS). The Company’s lead product DM199, is a drug candidate, a commercial potential as a therapy for CKD and AIS. DM199 is a recombinant form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) produced primarily in the kidneys, pancreas and salivary glands that plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels, which decreases vascular resistance) in the body, as well as an important role in inflammation and oxidative stress.